Overexpression of p53 has been reported to play a role in the development of neoplasms of the central nervous system. Meningiomas are generally benign intracranial tumors originating from the meninges. Overexpression of the p53 protein in meningiomas and an association with histological type and recurrence has been reported. Mutation of the TP53 gene leads to a more stable p53 protein in quantities high enough for detection by immunohistochemistry. In the search for these mutations the core domain of the TP53 gene of meningiomas has been analyzed. Only a very low incidence of mutations was reported. The apparent discordance between overexpression of p53 protein and TP53 gene mutations may be explained by mutations located outside the core domain. This issue was addressed in the present study. All 11 exons of 17 meningiomas were analyzed for DNA alterations by PCR single-strand conformation polymorphism (PCR-SS-CP) analysis with subsequent sequencing. PCR-SSCP analysis showed a various number of band shifts and nucleotide alterations, caused either by alterations in the flanking introns or common polymorphisms (codon 36 and 72). The allele frequencies of the polymorphisms found in this small population of tumors resemble the frequencies reported in the literature. In addition, three nucleotide changes located in introns 2, 3 and 7 were found in 11, 3 and 4, respectively, of 17 specimens. Based on this study and on reports by others we conclude that it is not very likely that TP53 mutations are involved in the etiology of meningiomas. (Int J Biol Markers, 2002; 17: 42-8) 
INTRODUCTION
The TP53 tumor suppressor gene is located on the short arm of chromosome 17 and encodes a 53-kDa nuclear phosphoprotein involved in the regulation of proliferation, DNA repair, and induction of apoptosis (1, 2) . Abnormalities of the TP53 gene have been reported to occur frequently in a wide spectrum of human cancers (3) . The wild-type p53 product suppresses transformation, whereas the mutated p53 protein may inactivate the wild-type p53 function, allowing DNA replication on a damaged template and therefore resulting in cell transformation (4) .
p53 has been reported to play a role in the development of neoplasms of the central nervous system (CNS) (5) . Meningiomas, generally benign intracranial tumors deriving from the meninges, account for at least 15% of all CNS tumors (6) . Overexpression of the p53 protein in a substantial number of meningiomas has been reported by several authors and there may be a connection between p53 expression and histological subtype and recurrence (7) (8) (9) (10) (11) . One of the main causes of p53 overexpression are mutations in the TP53 gene (12, 13) . In the search for these mutations in meningiomas the core domain of the TP53 gene has been extensively investigated, but only a small percentage of mutations were found (14) (15) (16) . This discordance may be explained by mutations located outside the core domain, of which it is known that they may contribute to p53 protein overexpression (17) . To elucidate the role of TP53 gene mutations in the etiology of meningiomas, knowledge about the mutation frequency of exons not included in the core domain is required.
In this study we used single-strand conformation polymorphism (SSCP) analysis of polymerase chain reaction (PCR) products with subsequent sequencing, to analyze mutations in exons 1-11 of the TP53 gene of 17 meningiomas of various histological subtypes (see Table I ).
MATERIAL AND METHODS

Tissues
Seventeen patients with meningeal tumors diagnosed at the De Wever Hospital (Heerlen, The Netherlands) between 1997 and 2000 were included in our study. The study was conducted in accordance with the guidelines of the local ethics committee. The characteristics of the tissues are shown in Table I .
DNA extraction and PCR analysis
Meningiomas were stored at -80°C until used for DNA isolation. DNA was isolated according to standard experimental procedures using a DNA isolation kit (Qiagen, Germantown, USA). The coding regions for the TP53 gene were amplified by the polymerase chain reaction (PCR). The sequences of the TP53 primers, the predicted sizes of the amplified products and restriction enzymes used are depicted in Table II . PCR primers were derived from Kropveld et al (18) . The PCR reaction was performed in a 50-µL reaction mixture containing 100 ng of genomic DNA, 10 mM dNTP, 200 ng each of the primers, 1.0-2.5 mM MgCl 2 (see Tab. II), Mg 2+ -free PCR buffer (10 mM Tris and 50 mM KCl, pH 8.3) and 1.25 U AmpliTaqGold (Roche Diagnostics, Mannheim, GmbH). After a first step of denaturation (10 min, 95°C) 35 cycles of PCR amplification 30 sec at 94°C, 30 sec at annealing temperature as shown in Table I , and 45 sec at 72°C were carried out, followed by 10 min at 72°C final extension in a GeneAmp PCR system 2400 thermal cycler (Perkin Elmer, Wellesley, USA). Amplified fragments were purified using a PCR purification spin kit (JETQuick, Genomed, GmbH). The PCR product was digested with restriction enzymes according to standard experimental procedures using restriction enzymes and SuRE/Cut buffer (Roche Diagnostics, Mannheim, GmbH) depicted in Table II . 
Single strand conformational polymorphism (SSCP) analysis and sequencing
Amplified and purified fragments were analyzed for SSCP using a GeneGel Excel 12.5/24 kit (Pharmacia Biotech, NJ, USA) at 5, 15 and 30°C. For most exons excellent results were obtained at 15°C (600 V, 30W, 30 mA) and a running time of 2-5.5 hours. PCR products of each exon containing a single mutation in the 5' primer region were made and used as positive control. Following SSCP analysis, suspect PCR products were used for direct sequencing. Double-strand PCR products were sequenced by the dideoxy-chain-termination method (19) using the Dye Primer Cycle Sequencing Ready Reaction Kit with Taq FS (ABI, Perkin Elmer (Applied Biosystem), Wellesley, USA). The PCR primers were used as sequencing primers (3.2 pmol) for direct sequencing of the amplified exon in both orientations. The sequence reaction was performed in a 15-µL reaction mixture containing 50 ng purified PCR poduct, 5 µL Terminator Ready Reaction Mix (ABI, Perkin Elmer, Wellesley, USA) and 3.2 pmol primer. After denaturation (1 min, 96°C) 30 cycles of sequencing for 10 sec at 96°C, 55 sec at 50°C and 4 min at 60°C, followed by hold at 10°C, were carried out in a GeneAmp PCR system 2400 thermal cycle (Perkin Elmer, Wellesley, USA). The extension products were purified using the ethanol sodium acetate precipitation method. The purified sequence products were separated on a 6% denaturating polyacrylamide gel using an automated DNA sequencer (373A, ABI, Perkin Elmer (Applied Biosystem), Wellesley, USA). Mutations were manually identified by multisequence analysis to validate the distinction between background and mutations by comparing sequence profiles of many samples.
RESULTS
The characteristics of the patients and histological types of the meningiomas and PCR-SSCP are shown in Table I . All exons of the TP53 gene were amplified with PCR using primers located in flanking introns (Tab. II). When the total PCR product length was more than 300 base pairs, the products were digested enzymatically to assure optimal mutation detection sensitivity.
PCR-SSCP analysis
Among the 17 meningiomas analyzed no band shifts were observed in SSCP analysis of exon 1 and 8 to 11. All positive controls of all exons did show a mobility shift as exemplified in Figure 1 .
Of the PCR products of exons 1-11, exons 2 to 7 showed multiple band mobility changes. Of the 17 meningiomas examined 12 showed a band shift in SSCP analysis of the PCR product of a combination of exons 2 and 3 (Tab. I). Ten meningiomas showed three different migration patterns of exon 4 PCR-SSCP products, possibly indicating different nucleotide alterations. Four of the meningiomas showed combinations of band shifts of exon 4 (see #1-4 in Fig. 1, left panel) . In three of the 17 meningiomas SSCP analysis revealed band shifts for the combination of exon 5 and 6 PCR products. In 4/17 meningiomas also mobility changes were found for the PCR products of exon 7. All suspected PCR products, the wild type and the positive controls were directly analyzed by sequencing and compared with TP53 database sequences.
Direct DNA sequence
To characterize the nucleotide sequence alterations detected by mobility shifts in PCR-SSCP analysis, the PCR products were sequenced with the same primers as were used for PCR-SSCP analysis. The overall results are shown in Table III . An example of sequence analysis of exon 4 is shown in Figure 2 (right panel). The mobility shifts of exon 4 PCR products appeared to be caused by two common polymorphisms and an additional mutation in intron 3 ( Fig. 2; specimen #2 ). The first polymorphism is a point mutation in codon 72, CGC to CCC resulting in an amino acid change of ARG to PRO. The allele frequencies found in 17 meningiomas were 0.71 for CGC and 0.29 for CCC. The second polymorphism in exon 4 was a nucleotide change in codon 36, CCG to CCA, and the allele frequencies were 0.94 for CCG and 0.06 for CCA. This nucleotide alteration does not lead to a different amino acid change. Besides two polymorphisms of exon 4, three meningiomas also showed a point mutation in intron 3 (65bp 3'exon3). The mobility shift of exon 2-3 PCR products was explained by a point mutation 38 bp off the 3' side of exon 2, G>C with allele frequencies of 0.3 and 0.7, respectively. No further mutations were found in the coding region. The mobility shift of exon 7 PCR products was explained by two point mutations in intron 7 (72 and 97 bp 3'exon7, respectively). Sequence analysis of abnormal PCR-SSCP products of the combination of exon 5-6 did not reveal mutations in these products.
DISCUSSION
TP53 gene alterations play a role in the pathogenesis of many different types of tumors. Wild-type p53 induces cell cycle arrest, preventing DNA replication errors and allowing time for DNA repair. It has also been linked to programmed cell death or apoptosis of cell types containing critical levels of DNA damage (20) . Dysfunction of TP53 caused either by mutation or by inactivation of the wild-type protein may therefore promote neogenesis by perpetuating errors in DNA (4, 21) . In normal cells wild-type p53 is present only in minute quantities. Mutations in the TP53 gene may lead to a more stable mutated p53 protein resulting in quantities high enough for detection by immunohistochemistry (IHC) (15, 22) .
Several authors have described p53 expression in several subtypes of meningioma with IHC (8, 9, 22, 23) . Ohkouda et al and other authors reported clinical significance for p53 expression in meningioma since an association was found between p53 immunoreactivity and histological type or recurrence (9) (10) (11) 24) . Wang et al found p53 expression in four out of five atypical meningiomas but in non of the 19 benign meningiomas investigated. They therefore concluded that p53 could be considered (15) . However, other authors could not confirm these observations (22, 25) . Although overexpression of the p53 protein is found in approximately 36% of meningiomas (7) (8) (9) (10) (11) , TP53 gene alterations were reported in only 4/126 specimens (see Table IV ). This suggests that TP53 mutations are not related to positive immunohistochemistry results and are not likely to play a major role in the etiology of meningiomas. All reports, however, focused on just half of the TP53 exons, i.e., exons 5-9. This may have resulted in underestimation of the actual TP53 mutation frequencies in meningiomas. Kropveld et al reported mutations located outside the hot spot region that contained 33% of the mutations found in head and neck squamous cell carcinoma (17) . This indicates that all TP53 exons should be analyzed before a role of TP53 mutations in menin-giomas can be excluded.
In the present study we have used PCR-SSCP analysis for detecting mutations in all exons of the human TP53 gene in 17 meningioma specimens. The effectiveness of this method in detecting mutations with SSCP-PCR is reportedly high (26, 27) . PCR products with a single mutation were used as positive controls. Several exons showed differential band migration by SSCP analysis and direct sequencing of the suspected PCR products revealed several nucleotide alterations. In exon 4 of the TP53 gene two types of polymorphism were present. A polymorphism at codon 72 results in translation to either arginine or proline. The allelic frequencies, 0.71p53Arg and 0.29p53Pro, found in the tissues of our meningioma patients, corresponded with those described for other tissues (28) (29) (30) . This polymorphism has been reported to be (14, 15, 27) . All TP53 exons are depicted above, with below the functional and structural domains of the p53 protein. Figure adapted from (42) . TAD, transactivation domain; DBD, DNA-binding domain; TD, tetradimerization domain; CRD, c-terminus regulatory domain associated with a susceptibility to several types of cancer. The arginine phenotype may confer protection against development of human papillomavirus-associated vulval neoplasia as shown in a female population from the UK (31) . Codon 72 polymorphism also seems to affect the risk of lung cancer related or unrelated to smoking (32) (33) (34) (35) . Several other population studies in patients with cervical cancer in the UK and Taiwan, in smoking-related non-small cell lung cancer patients, and in a Chinese population suffering from various types of cancer, however, revealed no association with codon 72 polymorphism (35) (36) (37) (38) (39) . Although no healthy subjects were included, the allele frequencies found in the present study, which are similar to those in published control populations (28) (29) (30) , do not point to a major role for codon 72 polymorphism in meningioma development. The second polymorphism observed was a nucleotide change in codon 36 which does not lead to an amino acid change but eliminates a FinI restriction site and creates a BccI site. The allelic frequencies found in meningiomas also correspond with those found for other populations (40) . To our knowledge the allele frequencies of these two polymorphisms of exon 4 have not been described previously for meningiomas. Sequence analysis of abnormal PCR-SSCP products of exons 5-6 could not demonstrate that these band shifts were caused by mutations in the combination exon 5 and 6 PCR products. These band shifts might be due to an SSCP artifact. Several combinations of intronic mutations or polymorphism were found. Whether the frequencies of occurrence of combinations of mutations have any biological significance is not known and could not be verified in this study due to the small sample size.
No nucleotide alterations could be detected in 11 exons of the TP53 gene that could reveal a role for TP53 mutations in the etiology of meningiomas. Other possibilities, such as mdm-2 expression, may contribute to a greater extent to the p53 overexpression found in meningiomas. Mdm-2 protein is involved in the stabilization of p53, resulting in a possible accumulation of the wildtype protein (41) . Indeed, mdm-2 expression has been reported in meningiomas showing p53 expression (9) .
In summary, in the present study we analyzed DNA of 17 meningiomas for mutations located in exons 1 to exon 11. Although SSCP showed a various number of band shifts in several exons, only nucleotide alterations could be found that were caused by alterations in the flanking introns or caused by known polymorphisms. Based on this study and on reports by others, our conclusion is that TP53 mutations are not very likely to be involved in the etiology of meningiomas.
